drugset / Trial / NCT00907933
Intranasal SB-705498 in Healthy Volunteers
RandomizedCrossoverDouble-blindTreatment
Summary
This is a First Time in Human (FTIH) study to investigate the safety, tolerability and pharmacokinetics (PK) of a) single, escalating and b) twice-daily 14 days repeat doses of intranasal SB-705498 in healthy volunteers (HVT). The safety and tolerability of single intranasal 498 dosing will be assessed and established before initiating the evaluation of repeat intranasal 498 dosing.
Timeline
- Start
- 2008-11-10
- Primary completion
- 2009-02-11
- Completion
- 2009-02-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SB-705498 | Small molecule | 0.5 mg | Intranasal |
| Subject | SB-705498 | Small molecule | 1.5 mg | Intranasal |
| Subject | SB-705498 | Small molecule | 3 mg | Intranasal |
| Subject | SB-705498 | Small molecule | 6 mg | Intranasal |
| Subject | SB-705498 | Small molecule | 12 mg | Intranasal |